Atrial fibrillation is the most common sustained cardiac arrhythmia. Its prevalence increases with age, reaching 5% among subjects over 65 years of age. Recently, evaluation of the best therapeutic approach to patients with atrial fibrillation has been the object of two multicenter clinical trials that have compared a strategy of rhythm control and one of rate control. The Atrial Fibrillation Follow-up Investigation of Rhythm Management trial enrolled a total of 4,060 patients with a mean age of 69.7 years. After a mean follow-up of 5 years, total mortality was 24% in the rhythm control group and 21% in the rate control group, leading to a hazard ratio of 1.15 (p = 0.08). Similar results were found in the smaller Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study. The two studies clearly indicate that rate control is not inferior to rhythm control in the general population of patients with atrial fibrillation and that the restoration of sinus rhythm should not be pursued aggressively. The data also suggest the opportunity for adequate anticoagulation among patients assigned to the rhythm control strategy. The characteristics of the patients enrolled as well as the analysis of subgroups suggest that the preference toward a rate control strategy may not apply to young patients who are moderately or highly symptomatic for atrial fibrillation, nor to patients with heart failure, in whom the arrhythmia may contribute to the progression of the disease. For these two classes of patients, rhythm control may still be an attractive option.

Journal Section:
Review
Keywords:
Antiarrhythmic drugs, Anticoagulation, Atrial fibrillation, Heart failure
This content is only available via PDF.
© 2003 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2003
You do not currently have access to this content.